(Q55471392)

12 July 2018

title

Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. (English)

1 reference

12 July 2018

pediatric low-grade glioma

main subject

patient

0 references

1 reference

1 reference

1 reference

8

Eric Bouffet

1 reference

12 July 2018

1

Lucie Lafay-Cousin

1 reference

12 July 2018

6

Uri Tabori

1 reference

12 July 2018

5

Ute Bartels

1 reference

12 July 2018

Stefan Holm

2

1 reference

12 July 2018

Ibrahim Qaddoumi

series ordinal

3

1 reference

12 July 2018

Gary Nicolin

series ordinal

4

1 reference

12 July 2018

Annie Huang

series ordinal

7

1 reference

12 July 2018

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 July 2018

published in

Cancer

1 reference

12 July 2018

volume

103

1 reference

12 July 2018

issue

12

1 reference

12 July 2018

page(s)

2636-2642

1 reference

12 July 2018

Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Response of pediatric low grade gliomas to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

High response rate to cisplatin/etoposide regimen in childhood low-grade glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Hypersensitivity reactions to cisplatin and carboplatin--a report on six cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Clinical features of hypersensitivity reactions to carboplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Hypersensitivity reactions to carboplatin in children.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

[HIT-LGG: effectiveness of carboplatin-vincristine in progressive low-grade gliomas of childhood--an interim report]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Hypersensitivity to carboplatin in children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Weekly dosing of carboplatin increases risk of allergy in children.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Anaphylaxis to carboplatin following multiple previous uncomplicated courses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Development and implementation of a carboplatin desensitization protocol for children with neurofibromatosis, type 1 and hypersensitivity reactions in an outpatient oncology clinic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Dominant lethal mutations induced in mouse spermatogonia by mechlorethamine, procarbazine and vincristine administered in 2-drug and 3-drug combinations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - a report from the French Society of Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Non-seminomatous ovarian germ cell tumours in children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21091

7 January 2021

Identifiers

DOI

10.1002/CNCR.21091

1 reference

12 July 2018

release_smkan3tzbbbr7mkyjr6xanwht4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/smkan3tzbbbr7mkyjr6xanwht4

24 November 2022

mapped directly with Wikidata item

1 reference

12 July 2018